Multiple myeloma is not bone cancer, but the confusion is understandable. It’s a cancer of plasma cells, a type of white blood cell that normally produces antibodies. These cancerous plasma cells accumulate inside the bone marrow, and roughly two-thirds of patients already have visible bone damage at the time of diagnosis. So while myeloma lives in your bones and destroys them, it originates in blood cells, not bone tissue.
Why Myeloma Feels Like Bone Cancer
The reason so many people associate myeloma with bone cancer is that bone pain is often the first and most prominent symptom. Myeloma cells don’t just passively sit in the marrow. They actively disrupt the normal cycle of bone maintenance by sending chemical signals that do two things simultaneously: they speed up the cells responsible for breaking down bone, and they suppress the cells responsible for building new bone. The result is bone that gets eaten away without being repaired.
This creates what are called osteolytic lesions, which are essentially holes in the bone. They weaken the skeleton to the point where fractures can happen from minimal force, sometimes just from standing up or twisting. The spine, ribs, pelvis, and skull are the most commonly affected areas. Nearly all myeloma patients will develop some degree of bone disease over the course of their illness.
What Actual Bone Cancer Looks Like
Primary bone cancers, like osteosarcoma and Ewing sarcoma, start in the bone cells themselves. They tend to occur in younger people, often teenagers, and usually form a single tumor in one bone, commonly in the arms or legs near the knee. Myeloma, by contrast, typically appears in adults over 60 and affects multiple bones throughout the body at once. The treatment approaches are completely different because the underlying biology is different.
There is one related condition worth knowing about: solitary plasmacytoma. This is a single plasma cell tumor that grows in one bone. It’s treated with targeted radiation, but patients require lifelong monitoring because it can progress to full multiple myeloma over time.
How Bone Damage Is Detected
Myeloma-related bone damage used to be found with a full-body set of X-rays called a skeletal survey. That approach has largely been replaced. Low-dose whole-body CT scans are now the recommended first-choice imaging technique, endorsed by the International Myeloma Working Group and major European oncology organizations. CT is significantly more sensitive at picking up bone loss, takes less time, and causes far less discomfort for patients who are already in pain from fractures or nerve compression.
MRI is sometimes used as well, particularly for evaluating the spine and pelvis or when CT results are inconclusive. PET-CT scans can also help distinguish active disease from old, healed lesions.
How Doctors Confirm the Diagnosis
Bone lesions alone don’t confirm myeloma. Doctors look for a combination of findings often summarized by the acronym CRAB: high calcium levels in the blood, kidney problems, anemia, and bone lesions. You need at least one of these, plus evidence of abnormal plasma cells in the bone marrow, to meet the diagnostic threshold. If less than 10% of the marrow contains cancerous plasma cells and only one bone lesion is present, the diagnosis may be solitary plasmacytoma rather than myeloma.
Protecting Bones During Treatment
Because bone destruction is so central to myeloma, bone-protecting medications are a standard part of treatment. These are given as intravenous infusions every three to four weeks and work by slowing down the cells that break down bone. An injectable alternative that works through a different mechanism is also available and has shown comparable effectiveness at preventing fractures and other skeletal complications.
Current guidelines from the American Society of Clinical Oncology recommend continuing bone-protecting therapy for up to two years. After that, the decision to continue depends on individual risk. If myeloma relapses, bone-protecting treatment is restarted. These medications don’t treat the cancer itself, but they can meaningfully reduce fractures, spinal compression, and the need for emergency bone procedures.
Survival and Outlook
Myeloma is considered treatable but not typically curable. The five-year relative survival rate is currently 63.7%, based on data from 2016 to 2022. That number has improved substantially over the past two decades thanks to newer drug combinations and better supportive care. The small number of patients (about 3%) diagnosed with truly localized disease have a five-year survival rate above 82%, though 96% of cases are classified as distant (widespread) at the time of diagnosis, reflecting the nature of a cancer that circulates through the marrow.
Bone damage from myeloma can be managed, and many patients maintain good quality of life for years with treatment. The key distinction to remember: myeloma is a blood cancer that happens to cause severe bone problems, not a cancer that starts in the bone itself. That distinction shapes everything about how it’s treated and monitored.